首页> 外文期刊>Modern Pathology >Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3): A Marker of Vascular Tumors with Presumed Lymphatic Differentiation, Including Kaposi's Sarcoma, Kaposiform and Dabska-Type Hemangioendotheliomas, and a Subset of Angiosarcomas
【24h】

Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3): A Marker of Vascular Tumors with Presumed Lymphatic Differentiation, Including Kaposi's Sarcoma, Kaposiform and Dabska-Type Hemangioendotheliomas, and a Subset of Angiosarcomas

机译:血管内皮生长因子受体3(VEGFR-3):标记为具有淋巴分化的血管肿瘤的标志物,包括卡波西氏肉瘤,卡波西氏和达布斯卡型血管内皮瘤,以及血管肉瘤的子集

获取原文
           

摘要

Recently, a novel monoclonal antibody to vascular endothelial growth factor receptor 3 (VEGFR-3), a tyrosine kinase receptor expressed almost exclusively by lymphatic endothelium in the adult, has been shown to react with a small number of cases of Kaposi's sarcoma (KS) and cutaneous lymphangiomas. We sought to extend these studies to a large number of well-characterized vascular neoplasms to evaluate diagnostic uses of this antibody and to determine whether it defines them in a thematic fashion. Formalin-fixed, paraffin-embedded sections from 70 vascular tumors were immunostained with antibodies to VEGFR-3 von Willebrand factor (vWF), and CD31. Anti–VEGFR-3 was positive in 23 of 24 KS, 8 of 16 angiosarcomas (AS), 6 of 6 kaposiform hemangioendotheliomas, 4 of 4 Dabska tumors, and 2 of 13 hemangiomas. Positively staining angiosarcomas were characterized either by a prominent lymphocytic component, a hobnail endothelial cell similar to that encountered in the Dabska tumor, or spindled areas resembling KS. No VEGFR-3 expression was noted in any cases of epithelioid hemangioendothelioma, pyogenic granuloma, littoral angioma, or stasis dermatitis. vWF expression was seen in 10 of 13 KS; 13 of 14 AS; 4 of 5 kaposiform hemangioendotheliomas; and all Dabska tumors, hemangiomas, lymphangiomas, epithelioid hemangioendotheliomas, vascular malformations, stasis dermatitis, and splenic littoral angiomas. CD31 expression was present in 12 of 13 KS, 13 of 14 AS, and in all other cases. Expression of VEGFR-3 is a very sensitive marker of KS, kaposiform, and Dabska-type hemangioendotheliomas, suggesting that all show at least partial lymphatic endothelial differentiation. Expression of VEGFR-3 does not reliably discriminate KS from AS. However, the expression of VEGFR-3 by certain AS having Kaposi-like areas, a prominent lymphocytic infiltrate, or hobnail endothelium may define subset(s) having phenotypic, if not pathogenetic and biologic, differences.
机译:最近,已显示出一种针对血管内皮生长因子受体3(VEGFR-3)的新型单克隆抗体,该抗体是成年人中几乎完全由淋巴内皮表达的酪氨酸激酶受体,已与少数情况下的卡波西氏肉瘤(KS)发生反应和皮肤淋巴管瘤。我们试图将这些研究扩展到大量特征明确的血管肿瘤,以评估该抗体的诊断用途并确定其是否以主题方式定义它们。用针对VEGFR-3血管性假血友病因子(vWF)和CD31的抗体对来自70个血管肿瘤的福尔马林固定,石蜡包埋的切片进行免疫染色。抗VEGFR-3在24 KS中的23例,16例血管肉瘤(AS)中的8例,6例kaposiform血管内皮瘤,6例4达布斯卡瘤和4例13血管瘤中呈阳性。阳性染色的血管肉瘤的特征是突出的淋巴细胞成分,类似于达布斯卡瘤中遇到的钉状内皮细胞或类似于KS的纺锤状区域。在上皮样血管内皮瘤,化脓性肉芽肿,沿海血管瘤或淤积性皮炎的任何病例中均未观察到VEGFR-3表达。在13个KS中有10个可见vWF表达; AS中14之13; 5个中的4个卡波西形血管内皮瘤;以及所有Dabska肿瘤,血管瘤,淋巴管瘤,上皮样血管内皮瘤,血管畸形,淤积性皮炎和脾脏沿海血管瘤。 CD31表达存在于13个KS中的12个,14个AS中的13个以及所有其他情况下。 VEGFR-3的表达是KS,kaposiform和Dabska型血管内皮瘤的非常敏感的标志物,提示它们均显示至少部分淋巴管内皮分化。 VEGFR-3的表达不能可靠地将KS与AS区分。但是,某些具有Kaposi样区域,突出的淋巴细胞浸润或钉状内皮的AS的VEGFR-3表达可能定义了具有表型差异(如果不是病原性和生物学差异)的子集。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号